This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The Rebisco Group’s Asia United Bank (AUB) is expecting profit to grow around 14 percent in 2018 as it expands its presence and clientele.
More and more financial institutions—including commercial banks, rural banks and cooperatives—have joined efforts to ease the process of doing business for construction firms through online payments.
THE GROWTH of banking stocks slowed during the quarter as market volatility sent investors into profit-taking mode despite the sector’s good earnings reports. For this quarter, however, most analysts interviewed have signaled a “buy” on the sector amid expectations of better earnings in the months ahead.
EW UBNC PSKXF CHIB BDOUY RZLLY PBB RCB SECB CKGOY AUB BDOUF BDO SYBJF PNB PHSXY PSE COL PTC
SINCE its establishment in 1997, the Asia United Bank (AUB) has continuously transformed its processes digitally to become, in the words of AUB Vice-President and Credit Cards Business Head Maria Magdalena V. Surtida, a “bank capable of superior innovation.” For instance, AUB fully automated its remittances in 2000, pioneered the straight-through processing of remittances in 2006, and introduced the first virtual teller kiosk in 2009 to speed up its branch transactions.
THE COUNTRY’s biggest banks opened the year on stronger footing as the first quarter sustained a streak of double-digit asset and loan growth, even as profitability slipped.
BDOUF BDO BDOUY AUB
PLDT, Inc. said its unit Voyager Innovations, Inc. is no longer pursuing a strategic partnership with Chinese tech giant Tencent Holdings, Ltd., after talks did not materialize.
GLO GTMEY 0700 GTMEF GLOPP GLOPA AUB
BANKS and e-money issuers have set up a new clearing house for real-time fund transfers yesterday, with seven lenders now able to process interbank transactions in a matter of seconds.
EW CHIB BDOUY RZLLY RCB SECB CKGOY AUB BDOUF BDO SYBJF PSB PTC
ASIA UNITED BANK (AUB) said it is introducing Alipay, the Alibaba Group Holding Ltd.’s mobile payment system, in the Philippines, a move expected to make it easier for Chinese tourists to pay for purchases using their electronic wallets.
BABA 0700 AUB
Mobile payment system Alipay will now be available in the Philippines to allow Chinese visitors in the country to pay using their electronic wallets, Asia United Bank (AUB) said.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...